Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Performance of FDG PET/CT in the Clinical Management of Breast Cancer
266
Zitationen
4
Autoren
2012
Jahr
Abstract
In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art positron emission tomography (PET)/computed tomography (CT) technology. The strengths and limitations of FDG PET/CT are examined in various clinical settings, and the following questions are answered: Is FDG PET/CT useful to differentiate malignant from benign breast lesions? Can FDG PET/CT replace sentinel node biopsy for axillary staging? What is the role of FDG PET/CT in initial staging of inflammatory or locally advanced breast cancer? What is the role of FDG PET/CT in initial staging of clinical stage IIA and IIB and primary operable stage IIIA breast cancer? How does FDG PET/CT compare with conventional techniques in the restaging of cancer in patients who are suspected of having disease recurrence? What is the role of FDG PET/CT in the assessment of early response to neoadjuvant therapy and of response to therapy for metastatic disease? Some recommendations for clinical practice are given.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 29.189 Zit.
Robust uncertainty principles: exact signal reconstruction from highly incomplete frequency information
2006 · 15.733 Zit.
Image processing with ImageJ
2004 · 11.903 Zit.
Fast robust automated brain extraction
2002 · 10.781 Zit.
Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images
2002 · 10.616 Zit.